Rigel Pharmaceuticals Inc... (RIGL)
NASDAQ: RIGL
· Real-Time Price · USD
41.34
1.21 (3.02%)
At close: Sep 05, 2025, 3:59 PM
41.40
0.15%
After-hours: Sep 05, 2025, 07:07 PM EDT
Rigel Pharmaceuticals Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Contract revenues from collaborations Revenue | 42.74M | 9.78M | n/a | -17.39M | -15.53M | -12.42M | n/a | 1M | 2M | 2.33M | 26.5M | -7.79M | -7.88M | -6.42M | 1.84M |
| Contract revenues from collaborations Revenue Growth | +336.85% | n/a | -100.00% | +12.01% | +25.01% | n/a | -100.00% | -49.88% | -13.76% | -91.22% | -440.16% | -1.12% | +22.68% | -448.97% | n/a |
| Discounts and allowances Revenue | -20.74M | -16.64M | 115.18M | 56.32M | 48.98M | 38.43M | 80.4M | -11.46M | -9.57M | -9.45M | -9.72M | 26.98M | 26.43M | 22.62M | -4.92M |
| Discounts and allowances Revenue Growth | +24.65% | -114.45% | +104.50% | +14.99% | +27.47% | -52.21% | -801.85% | +19.64% | +1.29% | -2.73% | -136.02% | +2.08% | +16.84% | -559.25% | n/a |
| Gross product sales Revenue | 79.69M | 60.19M | 79.97M | 38.93M | 33.45M | 26M | 56.67M | 38.59M | 33.46M | 33.2M | 32.5M | 19.19M | 18.55M | 16.2M | 22.49M |
| Gross product sales Revenue Growth | +32.40% | -24.73% | +105.44% | +16.37% | +28.64% | -54.11% | +46.87% | +15.33% | +0.78% | +2.14% | +69.38% | +3.44% | +14.53% | -27.99% | n/a |
| Milestone Revenue | 3M | 3M | n/a | n/a | n/a | n/a | n/a | 27.13M | 23.88M | 23.75M | 22.78M | n/a | n/a | n/a | 17.57M |
| Milestone Revenue Growth | 0.00% | n/a | n/a | n/a | n/a | n/a | n/a | +13.60% | +0.57% | +4.22% | n/a | n/a | n/a | n/a | n/a |
| Product sales, net Revenue | 58.95M | 43.55M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Product sales, net Revenue Growth | +35.36% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 29.26M | 27.71M | 29.52M | 27.04M | 28.05M | 28.45M | 26.85M | 24.86M | 26.31M | 27.73M | 32.17M | 25.9M | 26.98M | 27.4M | 24.52M | 22.88M | 22.38M | 22.12M | 21.82M | 17.43M | 18.92M | 18.43M | 18.31M | 18.12M | 18.21M | 19.95M | 21.37M | 18.07M | 17.07M | 13.49M | 14.65M | 7.95M | 7.82M | 7.41M | 7.15M | 4.56M | 4.77M | 4.42M | 4.72M | 4.28M | 4.1M | 4.72M |
| Selling, General, and Administrative Revenue Growth | +5.56% | -6.11% | +9.16% | -3.58% | -1.41% | +5.96% | +8.02% | -5.51% | -5.13% | -13.81% | +24.23% | -4.02% | -1.53% | +11.77% | +7.16% | +2.23% | +1.16% | +1.39% | +25.17% | -7.88% | +2.66% | +0.64% | +1.05% | -0.48% | -8.71% | -6.66% | +18.27% | +5.85% | +26.53% | -7.93% | +84.40% | +1.62% | +5.53% | +3.59% | +56.93% | -4.52% | +7.94% | -6.31% | +10.41% | +4.32% | -13.10% | n/a |
| Research and Development Revenue | 6.82M | 8.44M | 5.63M | 6.18M | 5.54M | 6.03M | 3.19M | 6.47M | 4.77M | 10.09M | 15.37M | 14.67M | 14.77M | 15.47M | 13.3M | 18.3M | 16.81M | 16.83M | 15.14M | 14.6M | 14.21M | 16.15M | 14.25M | 14.46M | 13.23M | 10.95M | 13.77M | 11.1M | 10.8M | 11.24M | 11.56M | 10.81M | 11.52M | 12.38M | 11.63M | 16.17M | 17.47M | 18.17M | 16.56M | 15.5M | 15.06M | 15.7M |
| Research and Development Revenue Growth | -19.14% | +49.79% | -8.90% | +11.59% | -8.07% | +89.14% | -50.80% | +35.69% | -52.70% | -34.34% | +4.77% | -0.68% | -4.57% | +16.31% | -27.30% | +8.88% | -0.11% | +11.15% | +3.68% | +2.72% | -11.98% | +13.35% | -1.49% | +9.35% | +20.80% | -20.47% | +24.06% | +2.78% | -3.96% | -2.76% | +6.97% | -6.21% | -6.88% | +6.38% | -28.06% | -7.43% | -3.88% | +9.72% | +6.85% | +2.94% | -4.10% | n/a |